Gib Efird
CFO
Get their honest, personalized take on your startup.
Sign in to pitch Gib →At a glance
- Full Name
- Gib Efird
- Title
- Chief Financial Officer & Head of Investor Relations
- Firm
- Arcline Investment Management, LP
- Firm Type
- Private equity (control buyouts of middle-market industrial/technology businesses) — not an angel/seed investor. *(The supplied stub labeling him "Angel Investors / Seed Round" appears to be inaccurate; see Background.)*
- Investment Stage
- Control buyouts / private equity (lower-middle to middle market); Arcline targets businesses with roughly $10M–$100M of EBITDA, valued up to ~$1B — not seed.
- Check Size
- Firm-level equity checks in the hundreds of millions per deal (e.g., its $1.8B take-private of Kaman); Arcline manages $30B+ in assets/commitments.
- Target Company Profile
- Niche, high-quality, market-leading middle-market companies with defensible positions and mission-critical products.
- Sector Focus
- Defense, aerospace, critical infrastructure services, industrial & medical technology, life sciences, and specialty materials/chemicals.
- Geographic Focus
- Primarily North America.
- Location
- Nashville, TN (per business directories); Arcline is headquartered in New York City with an office in San Francisco.
Background
Gib Efird is the Chief Financial Officer and Head of Investor Relations at Arcline Investment Management, a private equity firm founded in 2018 that pursues control buyouts of high-quality, middle-market businesses in the industrial and technology economy. In that role he oversees the firm's finance function and its relationships with limited partners/investors; org-chart data indicates he leads a team of roughly ten people. Arcline has grown rapidly since inception and today manages more than $30 billion in assets and capital commitments, concentrated in defense, aerospace, critical infrastructure, industrial and medical technology, life sciences, and specialty materials.
Before Arcline, Efird spent much of his career at PricewaterhouseCoopers (PwC), where he was promoted to Partner in the Advisory practice. As a member of PwC's Financial Due Diligence (transaction services) practice, he specialized in serving private equity clients — an ideal background for a PE-firm CFO. Earlier in his career he worked in PwC's Assurance practice (approximately 1996–1999) and then in the New Ventures Group at Idealab, the Pasadena-based technology incubator (approximately 1999–2002).
Efird earned a Bachelor's degree from the University of California, Santa Barbara, and an MBA from the University of Chicago Booth School of Business (2002–2004). He is a Certified Public Accountant licensed in California. He has also been active in his alumni community, serving as Vice President of the University of Chicago's Bay Area Alumni Association and founding the "Booth Breakfast Club" networking group for Chicago Booth alumni.
Important accuracy note: The stub described Gib Efird as an "Angel Investor" writing "Seed Round" checks. Available evidence does not support that. Efird is a finance-and-IR executive at a large-cap private equity firm, not a personal angel or seed-stage investor. If he makes personal angel investments, no public record of them was found. The profile below is written to reflect his actual, verifiable role.
Investment Thesis & Focus
- Efird's "investing" is institutional, not personal: he is the CFO/Head of IR of Arcline, whose strategy is control buyouts of niche, market-leading middle-market companies — the opposite end of the risk/stage spectrum from seed-stage angel investing.
- Stage/size: Arcline targets companies with roughly $10M–$100M of EBITDA, enterprise values up to ~$1 billion, and deploys equity checks in the hundreds of millions from multi-billion-dollar funds.
- Sectors: defense, aerospace, critical infrastructure services, industrial & medical technology, life sciences, and specialty materials/chemicals — "generalist within the industrial/technology economy."
- What makes the firm say yes: durable, mission-critical products; defensible niche market positions; strong management teams; and a "compounding" buy-and-build strategy supported by dedicated research, business-development, underwriting, and value-creation teams.
- As CFO/Head of IR specifically, Efird's focus is fund finance, reporting, and limited-partner (LP) relationships and fundraising — i.e., raising and managing capital, rather than sourcing company deals.
Notable Investments
- Kaman Corporation — Aerospace, defense, and medical components maker; Arcline took it private for ~$1.8 billion ($46.00/share cash), announced January 2024 and completed April 2024. Arcline's largest publicized deal to date.
- Broader Arcline portfolio spans defense, aerospace, industrial/medical technology, life sciences, and specialty materials companies (dozens of platform and add-on acquisitions across its funds); specific portfolio names beyond Kaman were not individually verified for this profile and are therefore not listed to avoid error.
Unlock the full research
Get how to approach them, recent activity, sources, contact links — plus pitch their AI twin for a candid read on your raise.
One-time. Stays unlocked for you.